FDA Allows Phase II-B Clinical Trial to Proceed Using Ischemic-Tolerant Mesenchymal Stem Cells to Treat Patients Suffering from Long-COVID
prweb.com
news
2022-10-20 19:15:00

Pulthera is a US-based biopharmaceutical company focusing on the treatment and management of long COVID. Long COVID is a significant health problem that has emerged in the wake of the pandemic. MSCs possess broad anti-inflammatory properties that may benefit the underlying condition. SONOMA, Calif. (PRWEB) October 20, 2022 Pulthera, LLC has received notice from the U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) that it can proceed with 'A Phase 2b, Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of Intravenous Allogenic Bone Marrow-derived Mesenchymal Stem Cells in Subjects with Dyspnea Associated with Post-acute Sequelae of SARS-CoV-2 Infection.
